ATH434
Small Molecule Target: α-synuclein, labile iron
Alterity Therapeutics
Most recent annual filing: 2025-08-29
- ATH434 filingby year-end 2026ATH434 filing, by year-end 2026, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
Technology platforms
Iron Chaperone Discovery Platform
Broad-spectrum platform targeting the interrelationship of metals and proteins in neurodegenerative and age-related diseases, including Parkinson's disease, Alzheimer's disease, Huntington disease, and potentially certain cancers, age-related macular degeneration, diabetes mellitus, and cardiovascular disease. Generates novel iron-modulating and zinc-modulating compounds from a chemical library of over 1000 validated compounds across diverse scaffolds.
Targets: labile iron, zinc, α-synuclein
Discontinued (2)
- PBT2 — Alzheimer's Disease · Phase 2 trial did not meet its primary endpoint and the program was ended; sub-licensed to Professor Colin Masters in March 2023
- PBT2 — Huntington's Disease · FDA placed PBT2 on Partial Clinical Hold based on toxicology findings that limited the dose; no further development described
Biotech Distilled coverage (7)
- 2026-08-14 UPDATE: Alterity Therapeutics (ATHE) - A Better Hand to Play at the Negotiating Table 🔒 Paid
- 2026-07-30 UPDATE: Alterity Therapeutics (ATHE) - The Runway Just Got Short 🔒 Paid
- 2026-07-07 UPDATE: Alterity Therapeutics (ATHE) - The Minutes Say “One Trial” 🔒 Paid
- 2026-06-09 UPDATE: Alterity Therapeutics (ATHE) - The Binary Resolves Clean
- 2026-05-01 UPDATE: Alterity Therapeutics (ATHE) - The FDA Says Yes (To The Easy Stuff) 🔒 Paid
- 2026-04-27 UPDATE: Alterity Therapeutics (ATHE) - The Regulatory Coil Tightens, and a New Scale Quietly Solves the 75mg Problem 🔒 Paid
- 2026-03-26 Alterity Therapeutics (ATHE) - Scientific Deep Dive for ATH434 and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.